Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 311 to 320 of 1332 total matches.
Gabapentin - A New Anticonvulsant
The Medical Letter on Drugs and Therapeutics • Apr 29, 1994 (Issue 921)
with antiepileptic activity are generally tried first for this indication.
PREVIOUSLY AVAILABLE DRUGS ...
Gabapentin (Neurontin - Parke-Davis), a cyclohexane acetic acid derivative, has been approved by the US Food and Drug Administration for use in addition to other antiepileptic drugs in patients with partial (focal) seizures with or without secondary generalization. Since this diagnostic category includes the largest number of patients with intractable epilepsy, new drugs with antiepileptic activity are generally tried first for this indication.
Treatment of Hypothermia
The Medical Letter on Drugs and Therapeutics • Dec 23, 1994 (Issue 938)
.
Hypothermia associated with exhaustion during outdoor sports activities can occur even at relatively mild ...
This winter physicians in many area may see patients suffering from hypothermia. Old age, lack of adequate housing, drug overdose and alcohol ingestion are often prediposing factors, but hypothermia also occurs in healthy young people after prolonged exposure to cold due to incapacitating trauma or cold water immersion. Hypothermia associated with exhaustionduring outdoor sports activities can occur even at relatively mild temperatures.
Two New Retinoids for Psoriasis
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997 (Issue 1013)
), an acetylenic retinoid prodrug, is rapidly converted to its active form, tazarotenic acid. Both compounds appear ...
The US Food and Drug Administration (FDA) has approved two new retinoids for treatment of psoriasis. Tazarotene gel 0.05% and 0.1% (Tazorac - Allergan) is being marketed for topical use in patients with stable, mild to moderate plaque psoriasis. Acitretin (Soriatane - Roche) is being promoted for systemic use in severe psoriasis.
Celecoxib for Arthritis
The Medical Letter on Drugs and Therapeutics • Jan 29, 1999 (Issue 1045)
inhibits the activity of CYP2D6 and therefore might increase serum concentrations of drugs metabolized ...
Celecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis and rheumatoid arthritis.
Novoseven for Non-Hemophilia Hemostasis
The Medical Letter on Drugs and Therapeutics • Apr 26, 2004 (Issue 1181)
NOVOSEVEN FOR NON-HEMOPHILIA HEMOSTASIS
Recombinant activated coagulation factor Vll (rFVIIa ...
Recombinant activated coagulation factor Vll (rFVIIa; NovoSeven - Novo Nordisk), which is marketed worldwide for treatment of bleeding episodes in hemophilia patients with inhibitors to factor VIII or IX, is now being used off-label to stop bleeding in patients who do not have hemophilia. An article in the lay press reported that one or two doses has stopped previously uncontrollable bleeding due to gunshot wounds (B Wysocki, Jr, Wall St Journal, March 17, 2004, page B1).
Prothrombin Complex Concentrates to Reverse Warfarin-Related Bleeding
The Medical Letter on Drugs and Therapeutics • Oct 03, 2011 (Issue 1374)
units/mL INR ...
Warfarin-related bleeding, especially intracranial hemorrhage,
can be catastrophic. Several products are available
to reverse warfarin’s anticoagulant effect.
Macitentan (Opsumit) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Feb 17, 2014 (Issue 1436)
or to 3 mg or 10 mg of the active
drug once daily. The composite primary endpoint
was time ...
The FDA has approved macitentan (ma" si ten' tan; Opsumit
– Actelion), for oral treatment of pulmonary arterial
hypertension (PAH). Macitentan is the second nonselective
endothelin receptor antagonist approved for PAH. It is a derivative
of bosentan (Tracleer), which is also manufactured
by Actelion, and is scheduled to become available generically
in 2015. Riociguat (Adempas), another new drug for
this indication, will be reviewed in a future issue.
Volibris
AspireAssist - A New Device for Weight Loss
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016 (Issue 1502)
), available only as an abstract, 171 patients
were randomized in a 2:1 ratio to active treatment ...
The FDA has approved AspireAssist (Aspire
Bariatrics), a weight-loss device that permits patients
to drain a portion of their stomach contents through
a gastrostomy tube into a toilet after each meal. It
is approved for long-term use in combination with
lifestyle modifications in adults ≥22 years old who
have a body mass index (BMI) of 35 to 55 and have
not been able to achieve and maintain weight loss with
nonsurgical therapy.
An Oral Cholera Vaccine for Travelers (Vaxchora)
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016 (Issue 1502)
during vaginal delivery.
DRUG INTERACTIONS — Antibiotics may be active
against the vaccine strain ...
The FDA has approved Vaxchora (PaxVax), a single-dose,
oral, live-attenuated cholera vaccine, to protect
against disease caused by Vibrio cholerae serogroup
O1 in adults 18-64 years old traveling to cholera-affected
areas. Vaxchora is the only cholera vaccine
available in the US. A whole-cell killed injectable
vaccine was previously approved, but is no longer
available in the US.
Exablate Neuro for Essential Tremor
The Medical Letter on Drugs and Therapeutics • Mar 27, 2017 (Issue 1517)
of everyday activities difficult. The most
effective drugs used to treat essential tremor are the
beta ...
The FDA has approved use of Exablate Neuro (Insightec)
for unilateral thalamotomy to treat medication-refractory
essential tremor in patients ≥22 years old.
Exablate Neuro uses magnetic resonance-guided
focused ultrasound (MRgFUS) to create lesions in the
ventral intermediate nucleus of the thalamus. MRgFUS
is also approved in the US for treatment of uterine
fibroids and for pain palliation of bone metastases.